• When Context Changes What a Cholesterol Signal Means

  2026-10-14

  A Filipin III signal is not synonymous with total cellular cholesterol. In the PHMG pulmonary-fibrosis study, it functioned as one readout within a broader model of macrophage lipid dysregulation, and its interpretation depended on the molecular species, cell model, comparator and orthogonal measurements.

• Anti-MYH11 Antibody: Evidence Overview

  2026-10-14

  The available record identifies MA3848 as the Anti-MYH11 Rabbit Monoclonal Antibody supplied by APExBIO. No matched research paper or product description was provided, so its documented identity can be summarized, but application-specific performance, specificity, validation, and outcomes cannot be independently assessed.

• Haloprogin: What the 1970 Study Showed

  2026-10-13

  A source-grounded overview of Harrison and colleagues’ 1970 evaluation of Haloprogin, covering its comparative antifungal spectrum, topical guinea-pig findings, and the limits of translating early preclinical evidence to human treatment.

• AZD6482 and DM1: What the Evidence Shows

  2026-10-13

  The supplied DM1 study identifies HSP90-linked, differentiation-dependent regulation of DMPK RNA and RNA foci, but it does not evaluate AZD6482. Current evidence therefore supports a clear separation between findings on HSP90 and product-level claims about this PI3Kβ inhibitor, with no direct basis for inferring an effect on DM1 biology.

• Sodium Chloride B7288: Identity and Evidence Scope

  2026-10-12

  Sodium chloride (NaCl), listed by APExBIO as SKU B7288, is an inorganic salt described for conceptual use in aqueous buffer preparation, ionic-strength control, osmotic balance, and selected cell culture media contexts. No matched research paper or product-specific outcome evidence was provided, so applicability and performance claims remain limited.

• HNF4A-AS1 and Sorafenib Resistance in HCC

  2026-10-12

  This 2024 Theranostics study links reduced HNF4A-AS1 to sorafenib resistance in hepatocellular carcinoma through DECR1-associated lipid remodeling and weaker ferroptosis susceptibility. Its multi-model evidence is mechanistically suggestive but remains preclinical and does not establish a clinical biomarker or treatment.

• 1-Myristoylglycerophosphocholine: Evidence Boundaries

  2026-10-11

  A source-grounded overview distinguishing evidence for LysoPC-related fibrosis mechanisms from evidence specifically concerning 1-myristoylglycerophosphocholine (14:0 Lyso-PC).

• Ciclesonide: Evidence, Uses, and Research Limits

  2026-10-10

  Ciclesonide is a glucocorticoid prodrug used in respiratory pharmacology research, with reported conversion to the more potent metabolite desisobutyryl-ciclesonide. This overview compares its asthma-related evidence with a separate 2026 study of desonide-based ERAD degraders and explains why the compounds should not be treated as interchangeable.

• CREC Carbapenemase Genes: Transmission Evidence

  2026-10-09

  Chen et al. characterize carbapenemase-encoding genes, mobile genetic elements, resistance profiles, and strain relatedness in 54 carbapenem-resistant Enterobacter cloacae isolates from eight teaching hospitals in Guangdong. The study links frequent plasmid-associated blaNDM-1 with multidrug resistance and substantial transfer potential, while also showing why molecular findings should not be equated automatically with documented hospital transmission.

• Chlorambucil in Cancer Research: Evidence and Limits

  2026-10-09

  A source-grounded overview of Chlorambucil research, emphasizing nitrogen mustard biology, assay interpretation, conceptual applications, evidence quality, and limits on translating in vitro findings to clinical or cross-model conclusions.

• Dual-Action Inhibitors and p38α Dephosphorylation

  2026-10-08

  A 2024 bioRxiv preprint reports that three kinase inhibitors can do more than block p38α catalytic activity: they also increase WIP1-mediated dephosphorylation of the kinase activation loop. Biochemical and X-ray structural evidence supports a model in which inhibitor-stabilized activation-loop conformations expose the phospho-threonine, offering a mechanistic framework for designing more selective kinase-directed interventions.

• Nystatin (Fungicidin): Evidence and Research Context

  2026-10-08

  Nystatin is a polyene antifungal whose research value centers on ergosterol-associated membrane disruption and activity against Candida species. This overview separates supplier-reported claims from peer-reviewed evidence, examines conceptual delivery applications, and defines the limits of extrapolating nanoparticle uptake findings to nystatin therapy.

• Brefeldin A and Endothelial Stress Biology

  2026-10-07

  A source-grounded perspective on how Brefeldin A can help translational researchers connect ER-to-Golgi trafficking, ER stress, cancer-cell phenotypes, and endothelial injury biology—while keeping mechanistic claims separate from clinical evidence.

• Ziprasidone Nanocrystals: Caco-2 Permeability Evidence

  2026-10-07

  Karaküçük and colleagues evaluated whether ziprasidone hydrochloride monohydrate nanocrystals could improve in vitro intestinal permeability relative to coarse drug powder. The study reported a 2.3-fold increase in Caco-2 permeability without a detectable reduction in cell viability, supporting nanocrystal formulation as a formulation-science strategy while leaving in vivo and clinical translation unresolved.

• HCN4 Heat Sensing and Heart Rate Control

  2026-10-06

  A 2025 Nature Communications study identifies an M407/Y409 motif in the HCN4 S4–S5 linker as a critical determinant of heat-induced current and heart-rate acceleration. By combining computational modeling, channel mutagenesis, SAN-cell recordings, isolated-heart studies, and genetically modified mice, the authors connect thermal sensing with the established cAMP pathway that regulates cardiac pacemaking.

8497 records 1/567 page Next 12345 下5页 Last page